Evidence map›Paper›PMID 9278246›Full record

ReviewMolecular and cellular biochemistry1997

DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors.

P D'Orléans-Juste, M G Sirois, E R Edelman, D Regoli, L H Pheng, G Bkaily, C J Lindsey

Abstract readReview
PubMed
In one paragraph

Review in Molecular and cellular biochemistry, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

P D'Orléans-JusteDepartment of Pharmacology, Faculty of Medicine, Université de Sherbrooke, Québec, Canada.
M G Sirois
E R Edelman
D Regoli
L H Pheng
G Bkaily
C J Lindsey
Université de Sherbrooke · CAHarvard–MIT Division of Health Sciences and Technology · USUniversidade Federal de São Paulo · BR

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS GM/ML 49039
6 · The paper itself

Abstract

Antisense oligodeoxynucleotide technology has contributed greatly to the overall understanding of both mRNA stability as well as translational processes leading to protein synthesis. Arrest of translational processes by DNA antisense strands usually reduces maximal effects of agonists without affecting their apparent affinities in treated isolated vascular or nonvascular preparations. In the present study, examples are given of DNA antisense oligonucleotide-induced repression of receptors for endothelins, kinins as well as of the platelet-derived growth factor. Furthermore, the efficiency of this technology illustrates the roles of protooncogenes (c-myc and c-myb) in wound-healing mechanisms. The overall mechanism of action of these oligomers is described and the relevance of size, chemical alterations and mode of delivery are illustrated. Release of oligophosphorothioates from polymer matrices and gels can produce a prolonged effect in vivo. Antisense oligonucleotides remain essential in experimental models for which receptor antagonists or selective inhibitors of intracellular components are currently unavailable.

Indexed as

Genetic TechniquesAnimalsEndothelinsGrowth SubstancesHumansKininsOligonucleotides, AntisensePlatelet-Derived Growth FactorReceptors, PeptideWound HealingEndothelinsGrowth SubstancesKininsOligonucleotides, AntisensePlatelet-Derived Growth FactorReceptors, Peptide

Identifiers

PMID9278246
OpenAlexW1497787965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.